Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 15, 2022 - Issue 8
Submit an article Journal homepage
806
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Non-viral infections and antimicrobial resistance in the time of COVID-19: what to expect?

Lyudmila BoyanovaDepartment of Medical Microbiology, Medical University of Sofia, Sofia, BulgariaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9622-0873View further author information
ORCID Icon,
Rumyana MarkovskaDepartment of Medical Microbiology, Medical University of Sofia, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0003-1634-8768View further author information
ORCID Icon,
Ivan MitovDepartment of Medical Microbiology, Medical University of Sofia, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0002-8417-0968View further author information
ORCID Icon &
Raina GergovaDepartment of Medical Microbiology, Medical University of Sofia, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0003-3605-6447View further author information
ORCID Icon
Pages 907-909 | Received 27 Feb 2022, Accepted 25 Jul 2022, Published online: 03 Aug 2022

References

  • Manohar P, Loh B, Nachimuthu R, et al. Secondary bacterial infections in patients with viral pneumonia. Front Med (Lausanne). 2020;7:420.
  • Papst L, Luzzati R, Carević B, et al., Antimicrobial use in hospitalised patients with COVID-19: an international multicentre point-prevalence study. Antibiotics. 2022;11(2):176.
  • Terreni M, Taccani M, Pregnolato M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. Molecules. 2021;26(9):2671.
  • Manohar P, Loh B, Leptihn S. Will the overuse of antibiotics during the Coronavirus pandemic accelerate antimicrobial resistance of bacteria? Infect Microb Dis. 2020;2(3):87–88.
  • Pakzad R, Malekifar P, Shateri Z, et al., Worldwide prevalence of microbial agents’ coinfection among COVID-19 patients: a comprehensive updated systematic review and meta-analysis. J Clin Lab Anal. 2022;36(1):e24151.
  • Goncalves Mendes Neto A, Lo KB, Wattoo A, et al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. J Med Virol. 2021;93(3):1489–1495.
  • Spigaglia P. Clostridioides difficile infection (CDI) during the COVID-19 pandemic. Anaerobe. 2022;74:102518.
  • Chung HS, Park JS, Shin BM. Laboratory diagnostic methods for Clostridioides difficile infection: the first systematic review and meta-analysis in Korea. Ann Lab Med. 2021;41(2):171–180.
  • Boyanova L, Markovska R, Mitov I. Multidrug resistance in anaerobes. Future Microbiology. 2019;14(12):1055–1064.
  • Pintado V, Ruiz-Garbajosa P, Escudero-Sanchez R, et al. Carbapenemase-producing Enterobacterales infections in COVID-19 patients. Infect Dis (Lond). 2022;54(1):36–45.
  • Das R, Kotra K, Singh P, et al. Alternative treatment strategies for secondary bacterial and fungal infections associated with COVID-19. Infect Dis Ther. 2022;11(1):53–78.
  • Lai CC, Chen SY, Ko WC, et al., Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. 2021;57(4):106324.
  • Kwon JH, Powderly WG. The post-antibiotic era is here. Science. 2021;373(6554):471.
  • Tran NK, Albahra S, Rashidi H, et al. Innovations in infectious disease testing: leveraging COVID-19 pandemic technologies for the future. Clin Biochem. 2022; S0009-9120(21)00341–6. DOI: 10.1016/j.clinbiochem.2021.12.011.
  • Manohar P, Loh B, Athira S, et al. Secondary bacterial infections during pulmonary viral disease: phage therapeutics as alternatives to antibiotics? Front Microbiol. 2020;11:1434.
  • Wu N, Chen LK, Zhu T. Phage therapy for secondary bacterial infections with COVID-19. Curr Opin Virol. 2022;52:9–14.
  • Al-Tawfiq JA, Alhumaid S, Alshukairi AN, et al., COVID-19 and mucormycosis superinfection: the perfect storm. Infection. 2021;49(5): 833–853.
  • Desoubeaux G, Coste AT, Imbert C, et al. Overview about Candida auris: what’s up 12 years after its first description? J Mycol Med. 2022;32(2):101248.
  • Hanson BM, Dinh AQ, Tran TT, et al. Candida auris invasive infections during a COVID-19 Case Surge. Antimicrob Agents Chemother. 2021;65(10):e0114621.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.